23andMe IPO
23andMe is a direct-to-consumer genetic testing company that provides ancestry and health information based on DNA analysis. The company has pivoted toward drug discovery and therapeutics development, leveraging its large genetic database to attract pharmaceutical partnerships and investor interest.
What We Know
23andMe went public in June 2021 through a SPAC merger with VG Acquisition Corp, initially valued at approximately $3.5 billion. The company trades on the NASDAQ under the ticker symbol 'ME'. Since its public debut, 23andMe's stock has faced significant challenges, including declining consumer genetic testing sales and regulatory scrutiny. The company has been focusing on its therapeutics division and pharmaceutical partnerships to drive future growth, though the stock has experienced substantial volatility since going public.
Frequently Asked Questions
Has 23andMe had an IPO?
Yes, 23andMe completed its IPO in June 2021 through a SPAC merger with VG Acquisition Corp. The genetic testing company now trades publicly on NASDAQ under ticker 'ME'.
When is the 23andMe IPO date?
23andMe already went public in June 2021, so there is no upcoming IPO date. The company completed its transition to public markets through a SPAC transaction.
How can I buy 23andMe stock?
You can purchase 23andMe stock through any major brokerage as it trades on NASDAQ under ticker 'ME'. Shares are available for trading during regular market hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts